Ophthalmologists using a proprietary confocal scanning laser ophthalmoscope with a fundus autofluorescence module can now quantify and track progression of geographic atrophy over time, thanks to the release of new software.
Modern Medicine Now
Male gender and younger age were identified as risk factors for IOP elevation after dexamethasone implant treatment in retinal vein occlusion in a recent subset analysis, but the elevated IOP did not seem to affect improvement in visual acuity or anatomic outcomes evaluated with optical coherence tomography.
For corneal researchers, gaining access to any sizable amount of high quality tissue has long been a challenge.
The results of the direct comparison of ranibizumab and bevacizumab after 1 year of treatment showed that the two drugs adminisred according to monthly and as-needed protocols produced significant decreases in retinal fluid with small amounts of residual fluid in patients with AMD.
'High-definition ocular coherence tomography update adds age-related macular degeneration, glaucoma tools
New software (version 6.0) introduced for a proprietary high-definition ocular coherence tomography platform provides researchers and clinicians an expanded set of diagnostic tools to use in the evaluation and management of patients with AMD and glaucoma.
On Jan. 30, vismodegib became the first drug approved by the FDA for the treatment of advanced basal cell carcinoma.
The use of laser to treat diabetic macular edema is often the topic of debate.
On Feb. 13, Merck announced that it received approval from the FDA to market its one-of-a-kind, preservative-free, prostaglandin analog, tafluprost ophthalmic solution 0.0015%, for lowering IOP in patients with open-angle glaucoma or ocular hypertension.
Based on our experience over the years, we believe the rules of investing and planning for retirement that one can feel confident in have changed forever.
Six years after OSI Pharmaceuticals Inc. bought Eyetech Pharmaceuticals Inc. for $650 million on the promise of its treatment for wet age-related macular degeneration, Valeant Pharmaceuticals International Inc. has announced it will acquire Eyetech for $22 million.